



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	ALEX-P03-060

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
/BD/ ↓ <						

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/BD/ ↓	BA	WO-9708320A1		03-06-1997	Morphosys Gesellschaft MBH		
	BB	WO-8806630A1		09-07-1988	Genex Corp.		
	BC	WO-9215679A1		09-17-1992	Protein Engineering Corp.		
	BD	WO-9627011A1		09-06-1996	Genentech, Inc.		
	BE	WO-8403508A1		09-13-1984	Dragoco Gerberding & Co. GMBH		
	BF	WO-8503508A1		08-15-1985	Cetus Corp.		
	BG	WO-04078937A2		09-16-2004	Alexion Pharmaceuticals, Inc.		
	BH	WO-03025202A2		03-27-2003	Alexion Pharmaceuticals, Inc.		
	BI	WO-97021450A		06-19-1997	Brigham and Women's Hospital		
	BJ	WO-99024565		05-20-1999	Gorczyński, R.M.		
↓	BK	WO-02095030		11-28-2002	Transplantation Tech, Inc.		
	BL	WO-02011762A2		02-14-2002	Gorczyński et al.		

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
-----------------------	--------------	--------------------	------------

10026224_1.DOC

10026224_1.DOC

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/736,188		
		Filing Date	December 15, 2003		
		First Named Inventor	Katherine S. Bowdish		
		Art Unit	1646		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	4	Attorney Docket Number	ALEX-P03-060

/BD/	BM	WO-02042332A2	05-30-2002	Transplantation Technologies	
------	----	---------------	------------	------------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	D ² D
/BD/	CA	AUCHINCLOSS, "Strategies to Induce Tolerance," Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).	
	CB	BARCLAY, "Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens," Immunology, 44:727-736(1981).	
	CC	BARCLAY and WARD, "Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2," European J. Biochemistry, 129:447-458(1982).	
	CD	BORRIELLO et al., "Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX - 2 membrane glycoprotein," Mammalian Genome, 9(2):114-118(1998).	
	CE	BORRIELLO et al., "MRC OX-2 Defines a Novel T Cell Costimulatory Pathway," J. Immunol., 158:4549-4554(1997).	
	CF	CHEN et al., "Cloning and characterization of the murine homologue of the rat/human MRC OX - 2 gene," Biochimica et Biophysica Acta, 1362(1):6-10(1997).	
	CG	GORCZYNSKI et al., "Increased expression of the novel molecule OX - 2 is involved in prolongation of murine renal allograft survival," Transplantation, 65(8):1106-1114(1998).	
	CH	GORCZYNSKI et al., "An Immunoadhesin Incorporating the Molecule OX-2 Is a Potent Immunosuppressant That Prolongs Allo- and Xenograft Survival," J. Immunol., 163:1654-1660(1999).	
	CI	PRESTON et al., "The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages," European J. of Immunol., 27(8):1911-1918(1997).	
	CJ	BACH, "Immunosuppressive therapy of autoimmune diseases," Immunology Today, 14(6):322-326(1993).	
	CK	BOHEN, S.P., "Variation in gene expression patterns in follicular lymphoma and the response to rituximab," PNAS, 100(4):1926-1930(2003).	
	CL	BOON, Thierry., "Toward a Genetic Analysis of Tumor Rejection Antigens," Advances in Cancer Res., 58:177-210(1992).	
	CM	BRODERICK et al., "Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis," Am. J. of Pathology, 161(5):1669-1677(2002).	
	CN	CLARK, D.A., "Intralipid as Treatment for Recurrent Unexplained Abortion?", Am. J. of Reprod. Immunol., 32:290-293(1994).	
	CO	CLARK et al., Amer. Soc. for Reprod. Medicine, 55th Annual Meeting (1999). Abstract Only.	
	CP	CLARK et al., "The OX-2 Tolerance Signal Molecule at the Fetomaternal Interface Determines Pregnancy Outcome," Amer. Journal of Reprod Immunol., 43:326(2000). Abstract Only.	
↓	CQ	CHAOUAT and CLARK, "FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer.	

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/736,188	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1646	
			Examiner Name	Not Yet Assigned	
Sheet	3	of	4	Attorney Docket Number	ALEX-P03-060

		J. of Reprod. Immunol., 45:108-115(2001).	
/BD/	CR	CLARK et al., "Fg12 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2," Mol. Human Reprod., 7:185-194(2001).	
	CS	COHEN, P.L., "Systemic Autoimmunity," in Fundamental Immunology, Fourth edition, W.E. Paul, Editor, Lippincott-Raven Publishers, Philadelphia, Ch. 33, p. 1067-1088(1999).	
	CT	DICK et al., "Control of Myeloid Activity During Retinal Inflammation," J. of Leukocyte Bio., 74:161-166(2003).	
	CU	GORCZYNSKI et al., "Does Successful Allopregnancy Mimic Transplantation Tolerance?", Graft, 4(5):338-345(2001).	
	CV	HOEK, et al., "Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)," Science, 290:1768-1771(2000).	
	CW	HUANG, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis," Pharmacol. Therapeutics, 86:201-215(2000).	
	CX	JAIN, "The next frontier of molecular medicine: Delivery of therapeutics," Nature Medicine, 4(6):655-657(1998).	
	CY	KEIL et al., American Society for Reproductive Immunology XX1st Annual Meeting, June 9-12, 2001, Chicago, IL., Page 343. Abstract Only.	
	CZ	KIM et al., "Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation," Cancer Res., 61:2031-2037(2001).	
	CA1	KJAERGAARD et al., "Therapeutic Efficacy of OX-40 Receptor Antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth," Cancer Res. 60:5514-5521(2000).	
	CB1	PARDOLL, Drew., "Therapeutic Vaccination for Cancer," Clin. Immunol., 95(1):S44-S62(2000).	
	CC1	RAGHEB et al., "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2," Immunol. Letters, 68:311-315(1999).	
	CD1	ROMAGNANI, Sergio., "Short Analytical Review: TH1 and TH2 in Human Diseases," Clin. Immunol. Immunopath., 80(3):225-235(1996).	
	CE1	ROSENWALD et al., "Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia," J. of Exp. Medicine, 194(11):1639-1647(2001).	
	CF1	STEINMAN, Lawrence., "Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy," Neuron, 24:511-514(1999).	
	CG1	TANGRI and RAGHUPATHY, "Expression of Cytokines in Placentas of Mice Undergoing Immunologically Mediated Spontaneous Fetal Resorptions," Biology of Reprod., 49:850-856(1993).	
	CH1	TODER et al., "Mouse Model for the Treatment of Immune Pregnancy Loss," Am. J. of Reprod. Immunol., 26:42-46(1991).	
	CI1	MJAALAND et al., "Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies," Eur. J. Immunol., 20:1457-1461(1990).	
	CJ1	BARCLAY et al., "Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure," Biochem. Soc. Symp., 51:149-157(1985).	
	CK1	MCCAUGHAN et al., "Characterization of the Human Homolog of the Rat MRC OX-2 Membrane Glycoprotein," Immunogenetics, 25:329-335(1987).	
	CL1	Paterson et al., "Antigens of Activated Rat T Lymphocytes Including A Molecule of 50,000 Mr Detected Only on CD4 Positive T Blasts," Molecular Immunology, 24(12):1281-1290(1987).	
	CM1	HEANEY et al., "Severe asthma treatment: need for characterising patients," Lancet, 365:974-976(2005).	
	CN1	GORCZYNSKI, "CD200 and its receptors as targets for immunoregulation," Current Opinion in	
Examiner Signature	/Brad Duffy/		Date Considered 07/17/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/736,188	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1646	
			Examiner Name	Not Yet Assigned	
Sheet	4	of	4	Attorney Docket Number	ALEX-P03-060

		Investigational Drugs, 6:483-488(2005).	
/BD/	CO1	Ni et al., "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival", FASEB Journal 13(5):A983(1999). Abstract Only.	
	CP1	CLARK et al., "Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages," Amer. J. Reprod. Immunol., 45:361(2001). Abstract Only.	
	CQ1	GORCZYNSKI, R.M., "Evidence for an Immunoregulatory Role of OX2 with Its Counter Ligand (OX2L) in the Regulation of Transplant Rejection, Fetal Loss, Autoimmunity and Tumor Growth," Arch. Immunol. et Ther. Exp., 49(4):303-309(2001).	
	CR1	NATHAN and MULLER, "Putting the Brakes on innate immunity: a regulatory role for CD200?", Nat Immunol., 2(1):17-19(2001).	
	CS1	CLARK et al., "Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal," Seminars in Immunol., 13(4):255-263(2001).	
	CT1	STUART et al., "Monkeying Around with Collagen Autoimmunity and Arthritis," Lab. Invest., 54(1):1-3(1986).	
	CU1	GORCZYNSKI and MARSDEN, "Modulation of CD200 receptors as a novel method of immunosuppression," Expert Opin. Ther. Patents, 13(5):711-715(2003). See also WIPO Patent No. WO02095030 assigned to Transplantation Tech, Inc.	
	CV1	TANG et al., "Pathogenesis of collagen-induced arthritis: modulation of disease by arthritogenic T-Cell epitope location," Immunology, 113:384-391.	
	CW1	MYERS et al., "Characterization of a Peptide Analog of a Determinant of Type II Collagen that Suppresses Collagen-Induced Arthritis," J. of Immunology, 161:3589-3595(1998).	
	CX1	GORCZYNSKI et al., "Anti-CD200R Ameliorates Collagen-Induced Arthritis in Mice," Clinical Immunol., 104(3):256-264(2002).	
	CY1	CHITNIS et al., "The Role of CD200 in Immune-Modulation and Neural Protection in EAE," Abstract, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, July 21, 2004. Abstract Only.	
	CZ1	BARCLAY et al., "CD200 and membrane protein interactions in the control of myeloid cells," Trends in Immunology, 23(6):2002.	
	CA2	GORCZYNSKI et al., "Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice," Clin. Exp. Immunol., 126:220-229(2001).	
V	CB2	ALIZADEH et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling," Nature, 403:503-511(2000).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1643
				Examiner Name	Bradley Duffy
Sheet	1	of	4	Attorney Docket Number	ALEX-P03-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)			
/BD/	BA	WO	97021450	06/1997	Borriello et al.	
/BD/	BB	WO	04078938	10/2004	Bowdish et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/BD/	CA	Banerjee, D., et al., "Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats," <i>Ocular Immunology and Inflammation</i> , 12(2):115-125 (2004).			
	CB	Blazer, B.R., et al., "CD28/B7 Interactions Are Required for Sustaining the Graft-Versus-Leukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells," <i>J. Immunol.</i> , 159:3460-3473 (1997).			
	CC	Bukovsky, A., et al., "Association of lymphoid cell markers with rat ascitic malignant cells," <i>IRCS Med. Sci.</i> , 11:866-867 (1983).			
	CD	Bukovsky, A., et al., "Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy," <i>Immunology</i> , 52:631-640 (1984).			
	CE	Bukovsky, A., et al., "The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube," <i>Immunology</i> , 48:587-596 (1983).			
	CF	Bukovsky, A., et al., "The ovarian follicle as a model for the cell-mediated control of tissue growth," <i>Cell Tissue Res.</i> , 236:717-724 (1984).			
	CG	Chen, D., et al., "Discrete Monoclonal Antibodies Define Functionally Important Epitopes in the CD200 Molecule Responsible for Immunosuppression Function," <i>Transplantation</i> , 79:282-288 (2005).			
	CH	Chen, D., et al., "Synthetic peptides from the N-terminal regions of CD200 and CD200R1 modulate immunosuppressive and anti-inflammatory effects of CD200-CD200R1 interaction," <i>International Immunology</i> , 17(3):289-296 (2005).			
	CI	Cherwinski, H.M., et al., "The CD200 Receptor Is a Novel and Potent Regulator of Murine and Human Mast Cell Function," <i>J. Immunol.</i> , 174:1348-1356 (2005).			
	CJ	Clark, M.J., et al., "MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain," <i>EMBO Journal</i> , 4(1):113-118 (1985).			
Examiner Signature	/Brad Duffy/			Date Considered	07/17/2007

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/736,188	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1643	
			Examiner Name	Bradley Duffy	
Sheet	2	of	4	Attorney Docket Number	ALEX-P03-060

/BD/	CK	Clarke, M.J., "MRC OX-2 lymphoid brain glycoprotein: S1 mapping suggests higher levels of abnormal RNA in the thymus than in the brain," Biochemical Society Transactions, 14:80-81 (1986).	
	CL	Fallarino, F., et al., "Murine Plasmacytoid Dendritic Cells Initiate the Immunosuppressive Pathway of Tryptophan Catabolism in Response to CD200 Receptor Engagement," J. Immunol., 173:3748-3754 (2004).	
	CM	Farber, U., et al., "Loss of heterozygosity on chromosome 3, bands q24->qter, in a diploid meningioma," Cytogenet Cell Genet, 57:157-158 (1991).	
	CN	Gorczyński, R., et al., "Evidence That an OX-2-Positive Cell Can Inhibit the Stimulation of Type 1 Cytokine Production by Bone Marrow-Derived B7-1 (and B7-2)-Positive Dendritic Cells," J. Immunol., 162:774-781 (1999).	
	CO	Gorczyński, R., et al., "CD200 Is a Ligand for All Members of the CD200R Family of Immunoregulatory Molecules," J. Immunol., 172:7744-7749 (2004).	
	CP	Gorczyński, R., et al., "Dendritic Cells Expressing TGFβ/IL-10, and CHO Cells With OX-2, Increase Graft Survival," Transplantation Proceedings, 33:1565-1566 (2001).	
	CQ	Gorczyński, R.M., "Role of Cytokines in Allograft Rejection," Current Pharmaceutical Design, 7:1039-1057 (2001).	
	CR	Gorczyński, R.M., "Synergy in Induction of Increased Renal Allograft Survival after Portal Vein Infusion of Dendritic Cells Transduced to Express TGFB and IL-10, along with Administration of CHO Cells Expressing the Regulatory Molecule OX-2," Clinical Immunology, 95(3):182-189 (2000).	
	CS	Gorczyński, R.M., "Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages," Eur. J. Immunol., 31:2331-2337 (2001).	
	CT	Gorczyński, R.M., et al., "A CD200FC Immunoadhesin Prolongs Rat Islet Xenograft Survival in Mice," Transplantation, 73(12):1948-1953 (2002).	
	CU	Gorczyński, R.M., et al., "Anti-Rat OX-2 Blocks Increased Small Intestinal Transplant Survival After Portal Vein Immunization," Transplantation Proceedings, 31:577-578 (1999).	
	CV	Gorczyński, R.M., et al., "Augmented Induction of CD4+ CD25+ Treg using Monoclonal Antibodies to CD200R," Transplantation, 79(4):488-491 (2005).	
	CW	Gorczyński, R.M., et al., "Augmented Induction of CD4+ CD25+ Treg using Monoclonal Antibodies to CD200R," Transplantation, 79(9):1180-1183 (2005).	
	CX	Gorczyński, R.M., et al., "CD200 Immunoadhesin Suppresses Collagen-Induced Arthritis in Mice," Clinical Immunology, 101(3):328-334 (2001).	
	CY	Gorczyński, R.M., et al., "Evidence for Persistent Expression of OX2 as a Necessary Component of Prolonged Renal Allograft Survival Following Portal Vein Immunization," Clinical Immunol., 97(1):69-78 (2000).	
	CZ	Gorczyński, R.M., et al., "Induction of Tolerance-Inducing Antigen-Presenting Cells in Bone Marrow Cultures In Vitro Using Monoclonal Antibodies to CD200R," Transplantation, 77(8):1138-1144 (2004).	
	CA1	Gorczyński, R.M., et al., "Interleukin-13, in Combination with Anti-Interleukin-12, Increases Graft Prolongation After Portal Venous Immunization with Cultured Allogeneic Bone Marrow-Derived Dendritic Cells," Transplantation, 62(11):1592-1600 (1996).	
↓	CB1	Gorczyński, R.M., et al., "Persistent expression of OX-2 is necessary for renal allograft survival," FASEB Journal, 14(6):A1069 (2000).	
	CC1	Gorczyński, R.M., et al., "Receptor Engagement on Cells Expressing a Ligand for the	

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/736,188	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1643	
			Examiner Name	Bradley Duffy	
Sheet	3	of	4	Attorney Docket Number	ALEX-P03-060

/BD/		Tolerance-Inducing Molecule OX2 Induces an Immunoregulatory Population That Inhibits Alloreactivity In Vitro and In Vivo," J. Immunol., 165:4854-4860 (2000).	
	CD1	Gorczyński, R.M., et al., "Regulation of Gene Expression of Murine MD-1 Regulates Subsequent T Cell Activation and Cytokine Production," J. of Immunology, 165:1925-1932 (2000).	
	CE1	Gorczyński, R.M., et al., "Structural and Functional Heterogeneity in the CD200R Family of Immunoregulatory Molecules and their Expression at the Fetomaternal Interface," AJRI, 52:147-163 (2004).	
	CF1	Gorczyński, R.M., et al., "The Same Immunoregulatory Molecules Contribute to Successful Pregnancy and Transplantation," AJRI, 48:18-26 (2002).	
	CG1	McCaughan, G.M., et al., "Identification of the human homologue of the rat lymphoid/brain antigen MRC OX-2," Australian and New Zealand Journal of Medicine 17: 142 (Abstract) (1987).	
	CH1	Hoek, R.M., et al., "Macrophage regulation by the B7.1/2 homologue OX2?", FASEB Journal, 14(6):A1232, Abstract #193.1 (2000).	
	CI1	Hutchings, N.J., et al., "Interactions of Cytoplasmic Region of OX2R Are Consistent with an Inhibitory Function," Annual Congress of the British Society for Immunology, 101(Supplement 1): 24, Abstract #10.6 (2000).	
	CJ1	Jeurissen, S.H.M., et al., "Characteristics and functional aspects of nonlymphoid cells in rat germinal centers, recognized by two monoclonal antibodies ED5 and ED6," Eur. J. Immunol., 16:562-568 (1986).	
	CK1	Kroese, F.G.M., et al., "Germinal centre formation and follicular antigen trapping in the spleen of lethally X-irradiated and reconstituted rats," Immunology, 57:99-104 (1986).	
	CL1	Kroese, F.G.M., et al., "The ontogeny of germinal centre forming capacity of neonatal rat spleen," Immunology, 60:597-602 (1987).	
	CM1	Marsh, M.N., "Functional and Structural Aspects of the Epithelial Lymphocyte, with Implications for Coeliac Disease and Tropical Sprue," Scandinavian Journal of Gastroenterology 114: 55-75 (1985).	
	CN1	McCaughan, G.W., et al., "The Gene for MRC OX-2 Membrane Glycoprotein Is Localized on Human Chromosome 3," Immunogenetics, 25:133-135 (1987).	
	CO1	McMaster, W.R., et al., "Identification of Ia glycoproteins in rat thymus and purification from rat spleen," Eur. J. Immunol., 9:426-433 (1979).	
	CP1	Mjaaland, S., et al., "The Localization of Antigen in Lymph Node Follicles of Congenitally Athymic Nude Rats," Scand. J. Immunol., 26:141-147 (1987).	
	CQ1	Mohammad, R.M., et al., "Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model," Leukemia, 10:130-137 (1996).	
	CR1	Morris, R.J., et al., "Sequential Expression of OX2 and Thy-1 Glycoproteins on the Neuronal Surface during Development," Dev. Neurosci., 9:33-44 (1987).	
	CS1	Nagelkerken L., et al., "Accessory Cell Function of Thoracic Duct Nonlymphoid Cells, Dendritic Cells, and Splenic Adherent Cells in the Brown-Norway Rat," Cellular Immunology, 93:520-531 (1985).	
	CT1	Ragheb, R.F., "Exploration of OX-2 function in tolerance induction and graft acceptance using an anti-mouse OX-2 monoclonal antibody," University of Toronto, Masters Abstracts International, 38(4):971-972 (2000).	
✓	CU1	Richards, S.J., et al., "Reported Sequence Homology Between Alzheimer Amyloid770 and the MCR OX-2 Antigen Does Not Predict Function," Brain Research Bulletin, 38(3):305-306	

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/736,188		
		Filing Date	December 15, 2003		
		First Named Inventor	Katherine S. Bowdish		
		Art Unit	1643		
		Examiner Name	Bradley Duffy		
Sheet	4	of	4	Attorney Docket Number	ALEX-P03-060

/BD/		(1995).	
	CV1	Rosenblum, M.D., et al., "CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance," <i>Blood</i> , 103(7):2691-2698 (2004).	
	CW1	Syme, R., et al., "Comparison of CD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients," <i>Stem Cells</i> , 23:74-81 (2005).	
	CX1	Taylor, N., et al., "Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge," <i>J. Immunol.</i> , 174:143-154 (2005).	
	CY1	Webb, M., et al., "Localisation of the MRC OX-2 Glycoprotein on the Surfaces of Neurones," <i>J. Neurochemistry</i> , 43:1061-1067 (1984).	
	CZ1	Wright, G.J., et al., "Lymphoid/Neuronal Cell Surface OX2 Glycoprotein Recognizes a Novel Receptor on Macrophages Implicated in the Control of Their Function," <i>Immunity</i> , 13:233-242 (2000).	
	CA2	Wright, G.J., et al., "The lymphoid/neuronal OX-2 glycoprotein interacts with a novel protein expressed by macrophages," <i>Tissue Antigens</i> , 55(Supplement 1): 11 (2000).	
	CB2	Wright, G.J., et al., "Viral homologues of cell surface proteins OX2 and CD47 have potential to regulate macrophage function," <i>Annual Congress of the British Society for Immunology</i> , 101(Supplement 1): 50 (2000).	
	CC2	Yang, C., et al., "Functional maturation and recent thymic emigrants in the periphery: development of alloreactivity correlates with the cyclic expression of CD45RC isoforms," <i>Eur. J. Immunol.</i> , 22:2261-2269 (1992).	
	CD2	Yu, X., et al., "The role of B7-CD28 co-stimulation in tumor rejection," <i>International Immunology</i> , 10(6):791-797 (1998).	
	CE2	Zhang, S., et al., "Molecular Mechanisms of CD200 Inhibition of Mast Cell Activation," <i>J. Immunol.</i> , 173:6786-6793 (2004).	
	CF2	Zheng, P., et al., "B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge," <i>Proc. Natl. Acad. Sci. USA</i> , 95:6284-6289 (1998).	
✓	CG2	Jansky, L., et al., "Dynamics of Cytokine Production in Human Peripheral Blood Mononuclear Cells Stimulated by LPS or Infected by <i>Borrelia</i> ," <i>Physiol. Res.</i> , 52:593-598 (2003).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1643
				Examiner Name	B. Duffy
Sheet	1	of	1	Attorney Docket Number	ALEX-P03-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/BD/	B1	WO-95018825	07/1995	Chung et al.		
/BD/	B2	WO-96038557	12/1996	Schwall et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
-----------------------	--------------	--------------------	------------



PTO/SB/08a/b (07-08)

Approved for use through 08/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/736,188		
		Filing Date	December 15, 2003		
		First Named Inventor	Katherine S. Bowdish		
		Art Unit	1643		
		Examiner Name	B. Duffy		
Sheet	1	of	1	Attorney Docket Number	ALEX-P03-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/BD/	CH2	FEUERSTEIN et al., 1999, Induction of Autoimmunity in a Transgenic Model of B Cell Receptor Peripheral Tolerance: Changes in Coreceptors and B Cell Receptor-Induced Tyrosine-Phosphoproteins; J. Immunol. 163:5287-5297		

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

Examiner Signature	/Brad Duffy/	Date Considered	07/17/2007
--------------------	--------------	-----------------	------------